SCHEMBL5427207

SCHEMBL5427207

Cc1ccc(CCNc2nc(C)nc3sc(C)cc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GALR3 O60755 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ NR2F2 P24468 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ HTT P42858 4/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ LMNA P02545 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MAPT P10636 5/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.44
▸ GBA1 P04062 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TP53 P04637 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5429124 0.91 KDM4E (0.49) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5433559 0.90 NPC1 (0.47) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5444805 0.90 SMN1; SMN2 (0.47) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5436049 0.90 NPC1 (0.47) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5438221 0.90 L3MBTL1 (0.48) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5426412 0.90 ALDH1A1 (0.50) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5429794 0.88 NPC1 (0.53) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5423234 0.86 NPC1 (0.46) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5444677 0.86 HTT (0.53) GALR3NPC1NR2F2RAB9AHTT
SCHEMBL5435676 0.86 MAPT (0.48) GALR3NPC1NR2F2RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275984-A1 Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275984-A1 Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors GRM2, GRIA2, GRM1 GALR3 305/4885NPC1 3777/4885NR2F2 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback